Camber Pharmaceuticals Launches Generic Vascepa®

Piscataway, NJ, March 8, 2024–Camber Pharmaceuticals is pleased to announce the addition of Icosapent Ethyl Capsules to its current portfolio.
Icosapent Ethyl Capsules are an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
Icosapent Ethyl Capsules are available in:
-
- 0.5 gram – 240 count bottles
- 1 gram – 120 count bottles
To find out more about Icosapent Ethyl Capsule, please visit https://www.camberpharma.com/icosapent
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection